Skip Nav Destination
Issues
1 May 2016
-
Cover Image
Cover Image
The tetravalent FAP-DR5 bispecific antibody (RG7386) is rationally designed to exhibit bivalent binding to FAP and DR5. By simultaneous binding to both targets, the death receptor on tumor cells is being hyper–cross-linked, resulting in strictly target-dependent apoptosis induction of cancer cells. For details, see the article by Brünker, Wartha, and colleagues beginning on page 946. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Reviews
Small Molecule Therapeutics
Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics
Carolyn C. Arpin; Stephen Mac; Yanlin Jiang; Huiwen Cheng; Michelle Grimard; Brent D.G. Page; Malgorzata M. Kamocka; Sina Haftchenary; Han Su; Daniel P. Ball; David A. Rosa; Ping-Shan Lai; Rodolfo F. Gómez-Biagi; Ahmed M. Ali; Rahul Rana; Helmut Hanenberg; Kagan Kerman; Kyle C. McElyea; George E. Sandusky; Patrick T. Gunning; Melissa L. Fishel
EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB
Gianluca Civenni; Nicole Longoni; Paula Costales; Cecilia Dallavalle; Cristina García Inclán; Domenico Albino; Luz Elena Nuñez; Francisco Morís; Giuseppina M. Carbone; Carlo V. Catapano
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma
Andrew Stiff; Enrico Caserta; Douglas W. Sborov; Gerard J. Nuovo; Xiaokui Mo; Sarah Y. Schlotter; Alessandro Canella; Emily Smith; Joseph Badway; Matthew Old; Alena Cristina Jaime-Ramirez; Pearlly Yan; Don M. Benson; John C. Byrd; Robert Baiocchi; Balveen Kaur; Craig C. Hofmeister; Flavia Pichiorri
Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non–Small Cell Lung Cancer
Jianguo Feng; Shirong Zhang; Kan Wu; Bing Wang; Jeffrey Y.C. Wong; Hong Jiang; Rujun Xu; Lisha Ying; Haixiu Huang; Xiaoliang Zheng; Xufeng Chen; Shenglin Ma
Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption
Leqin Xu; Jian Luo; Rongrong Jin; Zhiying Yue; Peng Sun; Zhengfeng Yang; Xinghai Yang; Wei Wan; Jishen Zhang; Shichang Li; Mingyao Liu; Jianru Xiao
Author Choice
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Kevin Hudson; Urs J. Hancox; Cath Trigwell; Robert McEwen; Urszula M. Polanska; Myria Nikolaou; Pablo Morentin Gutierrez; Alvaro Avivar-Valderas; Oona Delpuech; Phillippa Dudley; Lyndsey Hanson; Rebecca Ellston; Alys Jones; Marie Cumberbatch; Sabina C. Cosulich; Lara Ward; Francisco Cruzalegui; Stephen Green
Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia
Chaofeng Mu; Xiaoyan Wu; Helen Ma; Wenjing Tao; Guodong Zhang; Xiaojun Xia; Jianliang Shen; Junhua Mai; Tong Sun; Xiaoping Sun; Ralph B. Arlinghaus; Haifa Shen
Author Choice
7-(2-Thienyl)-7-Deazaadenosine (AB61), a New Potent Nucleoside Cytostatic with a Complex Mode of Action
Pavla Perlíková; Gabriela Rylová; Petr Nauš; Tomáš Elbert; Eva Tloušťová; Aurelie Bourderioux; Lenka Poštová Slavětínská; Kamil Motyka; Dalibor Doležal; Pawel Znojek; Alice Nová; Monika Harvanová; Petr Džubák; Michal Šiller; Jan Hlaváč; Marián Hajdúch; Michal Hocek
Large Molecule Therapeutics
Author Choice
Development of Novel Quaternary Ammonium Linkers for Antibody–Drug Conjugates
Patrick J. Burke; Joseph Z. Hamilton; Thomas A. Pires; Jocelyn R. Setter; Joshua H. Hunter; Julia H. Cochran; Andrew B. Waight; Kristine A. Gordon; Brian E. Toki; Kim K. Emmerton; Weiping Zeng; Ivan J. Stone; Peter D. Senter; Robert P. Lyon; Scott C. Jeffrey
Author Choice
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
Peter Brünker; Katharina Wartha; Thomas Friess; Sandra Grau-Richards; Inja Waldhauer; Claudia Ferrara Koller; Barbara Weiser; Meher Majety; Valeria Runza; Huifeng Niu; Kathryn Packman; Ningping Feng; Sherif Daouti; Ralf J. Hosse; Ekkehard Mössner; Thomas G. Weber; Frank Herting; Werner Scheuer; Hadassah Sade; Cuiying Shao; Bin Liu; Peng Wang; Gary Xu; Suzana Vega-Harring; Christian Klein; Klaus Bosslet; Pablo Umaña
Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design
Magdalena Dorywalska; Russell Dushin; Ludivine Moine; Santiago E. Farias; Dahui Zhou; Thayalan Navaratnam; Victor Lui; Adela Hasa-Moreno; Meritxell Galindo Casas; Thomas-Toan Tran; Kathy Delaria; Shu-Hui Liu; Davide Foletti; Christopher J. O'Donnell; Jaume Pons; David L. Shelton; Arvind Rajpal; Pavel Strop
A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells
Nils Lilienthal; Gregor Lohmann; Giuliano Crispatzu; Elena Vasyutina; Stefan Zittrich; Petra Mayer; Carmen Diana Herling; Mehmet Kemal Tur; Michael Hallek; Gabriele Pfitzer; Stefan Barth; Marco Herling
Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit
Philipp Emanuel Geyer; Matthias Maak; Ulrich Nitsche; Markus Perl; Alexander Novotny; Julia Slotta-Huspenina; Estelle Dransart; Anne Holtorf; Ludger Johannes; Klaus-Peter Janssen
Cancer Biology and Signal Transduction
Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma
Mayura Meerang; Karima Bérard; Emanuela Felley-Bosco; Olivia Lauk; Bart Vrugt; Andreas Boss; David Kenkel; Angela Broggini-Tenzer; Rolf A. Stahel; Stephan Arni; Walter Weder; Isabelle Opitz
Companion Diagnostics and Cancer Biomarkers
Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies
Daniel Azuara; Cristina Santos; Adriana Lopez-Doriga; Julieta Grasselli; Marga Nadal; Xavier Sanjuan; Fátima Marin; Joana Vidal; Robert Montal; Victor Moreno; Beatriz Bellosillo; Guillem Argiles; Elena Elez; Rodrigo Dienstmann; Clara Montagut; Josep Tabernero; Gabriel Capellá; Ramon Salazar
Author Choice
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose; Joel D. Leverson; Franklin Peale; Erwin R. Boghaert; Lisa D. Belmont; Nguyen Tan; Amy Young; Michael Mitten; Ellen Ingalla; Walter C. Darbonne; Anatol Oleksijew; Paul Tapang; Peng Yue; Jason Oeh; Leslie Lee; Sophie Maiga; Wayne J. Fairbrother; Martine Amiot; Andrew J. Souers; Deepak Sampath
Models and Technologies
Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer
Barbara M. Grüner; Isabel Winkelmann; Annette Feuchtinger; Na Sun; Benjamin Balluff; Nicole Teichmann; Alexander Herner; Evdokia Kalideris; Katja Steiger; Rickmer Braren; Michaela Aichler; Irene Esposito; Roland M. Schmid; Axel Walch; Jens T. Siveke
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.